SynAgile develops and commercializes noninvasive, continuous oral drug‑delivery therapeutics based on its proprietary OraFuse technology, with an initial focus on treating motor complications in Parkinson’s disease. Its lead product, DopaFuse, is a levodopa‑carbidopa delivery system described as the first non‑invasive, continuous option for levodopa administration and is intended to address motor fluctuations and dyskinesia. The company is running a Phase II trial of DopaFuse in Luxembourg, Italy and Spain. SynAgile announced the closing of a convertible debt financing of greater than $9 million to support its clinical and development plans. Proceeds are earmarked to complete the Phase II trial and to initiate manufacturing scale‑up in preparation for a Phase III trial. In conjunction with the financing, SynAgile appointed Michael McNamara to its board and named Dr. C. Warren Olanow as Chief Medical Officer. SynAgile Corporation, based in Wilson, Wyoming, develops and commercializes therapeutics using its proprietary OraFuse™ oral dosing technology. Its initial focus is treating debilitating motor complications in patients with Parkinson’s disease. Its lead program, the DopaFuse™ delivery system, is a non-invasive, continuous levodopa-carbidopa delivery system designed to treat motor fluctuations associated with Parkinson’s disease. The company closed a $10.4m equity financing led by affiliates of TAMCAP LLC. Proceeds from the round will be used to conduct the first-in-human, Phase 2 clinical trial of the DopaFuse system. SynAgile positions its platform to enable transformative therapeutics through oral dosing advances and to commercialize treatments addressing Parkinson’s motor complications.

Total raised

$19M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Sep 2021